FuturHealth expands digital health platform to boost convenience for oral GLP-1 drugs

Clinical guidance health platform FuturHealth has expanded its oral GLP-1 receptor agonist options with orforglipron — branded Foundayo by the pharmaceutical company Eli Lilly. The move comes as consumers seek more non-injectable treatment options. 

Foundayo has demonstrated glycemic control and weight loss in diverse patient populations in prior clinical trials, driving interest. Obese participants lost on average 12% of their body weight over 72 weeks when taking the highest dose, and experienced improved blood sugar control.

Oral weight loss supplements are growing in popularity as they offer the added convenience of a once-daily pill without taking food or water timing restrictions into account.

“What’s exciting about Foundayo is that it builds on what we already know works with GLP-1s, but removes the factor of needles, which is one of the biggest barriers to GLP-1 care for patients,” says Dr. Michael Snyder, in-house obesity specialist at FuturHealth. 

“The key is ensuring it’s used within a structured program that supports nutrition, muscle preservation, and long-term health instead of just weight loss alone. By treating GLP-1 medication as a catalyst to a healthier lifestyle, not the only solution, FuturHealth has helped 400,000 people and counting achieve sustainable results.”

Luke Mahoney, co-founder and CEO of FuturHealth, says the industry is entering a new phase of the GLP-1 category where access, affordability, and usability are increasing rapidly.

“Oral options like Foundayo are generally seen as far more approachable than injectables, and we’re going to see a much broader population engage with these therapies as they come to market at more accessible price points. Our role is to ensure that access is paired with the right clinical guidance, nutrition, and long-term support so patients can achieve meaningful, lasting results.”

The platform provides subscribers with information for both getting on and off the medication successfully.Avoiding weight regain

FuturHealth provides a subscription-based personalized care model to support long-term health, which includes US FDA-approved medications such as Eli Lilly’s Foundayo. Subscribers to the platform receive clinical nutrition, movement, and lifestyle guidance. It provides patients with information for both getting on and off the medication successfully.

Previous research has demonstrated the importance of nutritional guidance when using and discontinuing GLP-1 drugs, as it is a useful tool to keep the weight off by stabilizing appetite and energy.

A prior review cautioned that consumers who stop weight loss medication quickly regain the lost pounds, at a rate of 0.4 kg per month. The authors said that weight and risk markers for diabetes and heart disease are predicted to return to pre-treatment levels in under two years after discontinuing the drugs.

Another study found that 55% of obese people regained weight lost after quitting GLP-1 medication, and so did 45% of diabetic patients. It also found that 45% of obese participants and 56% of the diabetics kept losing weight or stayed the same when coming off the medication.